Skip to Main content Skip to Navigation
Journal articles

BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma

Abstract : BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma Venetoclax/ABT-199 is the first in the class of BCL2-specific BH3 mimetics and the most promising targeted therapy in oncology (Souers et al, 2013). Venetoclax is currently under investigation in multiple myeloma (MM), which is heterogeneous and includes either patients with a translocation on chromosome 14 with different chromosomes (4, 6, 11 or 16) or a hyperdiploidy. We demonstrated that venetoclax induces cell death in a subgroup harbouring the t(11;14) transloca-tion, expressing a high BCL2/MCL1 gene expression ratio, and that intrinsic venetoclax resistance is mediated by high MCL1 expression in MM cells (Touzeau et al, 2014). Preliminary results from an ongoing phase I clinical trial testing venetoclax in relapsed/refractory MM patients indicate that BCL2 inhibition has a tolerable safety profile and single agent activity mostly in t(11;14) patients (Kumar et al, 2015). The anticipated use of venetoclax in the treatment of MM lead us to explore the mechanisms of acquired veneto-clax resistance. We generated two venetoclax-resistant mye-loma cell lines using in vitro selection and derived resistant sublines (named-199R) from KMS12-PE and XG5 t(11;14) myeloma venetoclax-sensitive cell lines (Figs 1A, 2A) (Data S1). Both resistant sublines showed a strong reduction in V
Document type :
Journal articles
Complete list of metadatas

Cited literature [10 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-01353369
Contributor : Elizabeth Bernardo <>
Submitted on : Thursday, August 11, 2016 - 11:35:00 AM
Last modification on : Friday, June 19, 2020 - 3:08:47 AM
Long-term archiving on: : Saturday, November 12, 2016 - 12:12:01 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

Christelle Dousset, Sophie Maïga, Patricia Gomez-Bougie, Joy Le Coq, Cyrille Touzeau, et al.. BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma. British Journal of Haematology, Wiley, 2016, [Epub ahead of print]. ⟨10.1111/bjh.14251⟩. ⟨inserm-01353369⟩

Share

Metrics

Record views

304